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Despite the use of hepatitis B virus (HBV) vaccines and 
preventive measures, infection with HBV remains a ma-
jor global health problem. Patients with chronic kidney 
disease (CKD) are at an increased risk of acquiring HBV 
infections from shared dialysis equipment, increased ex-
posure to blood products, and immunodeﬁciency associ-
ated with CKD (1, 2). In addition, they may be more likely 
to develop chronic infections on exposure to HBV (1, 2), 
and HBV infection among CKD patients is associated with 
high rates of morbidity and mortality (3, 4). Vaccination 
is important both for preventing susceptible patients 
from acquiring HBV and for reducing the pool of HBV-
infected patients. HBV infection remains a concern in 
dialysis populations, because the vaccination programs 
have been less successful in these populations than in 
the general population. The causes of poor seroconver-
sion in CKD patients include malnutrition, uremia, and 
immunosuppression due to renal failure (5). 
In the current issue of Hepatitis Monthly, Behnam 
Hashemi et al. (6) compared the seroconversion rates of 
patients with diﬀerent stages of CKD who received the 
HBV vaccine. The overall seroconversion rate was found 
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to be 78%. This result was comparable with those of stud-
ies in patients with end stage renal disease (ESRD) (sero-
conversion rates, 60–90.5%) (7). The HBV vaccination is 
less eﬀective in patients with ESRD than in those with-
out CKD (7). The seroconversion rate among individuals 
without CKD was over 90% whereas that among patients 
with ESRD was only 50–60% (8). In addition, compared to 
patients without CKD, ESRD patients frequently showed 
lower seroconversion rates, lower peak antibody titers, 
and a more rapid decline of antibody levels (9).
Behnam Hashemi et al. showed that there was sig-
niﬁcant correlation between hepatitis B surface (HBs) 
antibody titer and the glomerular ﬁltration rate (GFR) 
(P = 0.001). However, there was no evident correlation 
between the seroconversion rate and severity of renal 
dysfunction. They showed that HBV vaccination in the 
early stages of CKD did not result in signiﬁcantly higher 
seroconversion rates than those achieved on HBV vacci-
nation in the late stages of CKD. Another study showed 
that there was no association between the response rate 
and degree of renal dysfunction in individuals with mild 
to moderate CKD (10). However, several studies showed 
that ESRD patients who were vaccinated before they re-
quired dialysis showed higher seroconversion rates and 
antibody titers than those who were undergoing dialysis 
when they received vaccination, suggesting a correlation 
betweenimmune response and degree of renal dysfunc-
tion (5, 7, 11). It is very important that HBV vaccination be 
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carried out in the early stage of CKD, since seroconver-
sion is correlated with the amount of GFR (5). DaRoza 
et al. in a large cohort study showed that patients with 
higher GFR levels showed a better immune response to 
the HBV vaccine (5). These diverse ﬁndings may be partly 
attributable to diﬀerent inclusion criteria; for example, 
the ESRD patients included in the study by DaRoza et al. 
(5) had a poorer GFR than that of the patients in the study 
by McNulty et al (10). Nonetheless, the strategies recom-
mended for improving seroconversion rates among 
ESRD patients include vaccination in the early stages 
of CKD (12). Furthermore, elderly patients with ESRD 
seemed to have a lower rate of seroconversion than that 
in the younger patients (10, 13). Behnam Hashemi et al., 
showed a signiﬁcant negative correlation between old 
age (> 60 years) with seroconversion rate. Advanced age, 
male gender, diabetes CKD patients, and previous blood 
transfusions are associated with poor seroconversion 
rates (7, 14). Advanced age negatively aﬀected the sero-
conversion rate regardless of the patient’s status (5, 7, 15).
In conclusion, HBV vaccination is necessary in CKD pa-
tients, because they are at a high-risk of developing HBV 
infections. Despite these controversial ﬁndings, many 
clinicians recommend that patients with CKD receive 
vaccination as soon as chronic progressive renal failure 
is diagnosed, and if possible, before dialysis is required.
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